Skip to content
HowShorted

Intra-Cellular Therapies Inc. short interest in 2024

In 2024, Intra-Cellular Therapies Inc.'s disclosed short interest ran from 3.64% of shares outstanding on 12 Jan 2024 to 1.87% on 31 Dec 2024, a change of -1.77 percentage points. The year's high was 4.31% on 15 May 2024 and its low 1.64% on 29 Nov 2024, averaging 3.00% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.95 days on 15 Apr 2024. Full history: Intra-Cellular Therapies Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Intra-Cellular Therapies Inc. in 2024

2024 in figures

Start of year
3.64% (12 Jan 2024)
End of year
1.87% (31 Dec 2024)
Change
-1.77 pp
High
4.31% (15 May 2024)
Low
1.64% (29 Nov 2024)
Average
3.00%
Highest days to cover
6.95 (15 Apr 2024)
SEC filings marked
9

Every report in 2024

Intra-Cellular Therapies Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20243.64%4.49
31 Jan 20244.22%4.63
15 Feb 20244.01%4.76
29 Feb 20243.84%4.1410-K filed, results (8-K)
15 Mar 20243.44%4.73
28 Mar 20243.60%5.55
15 Apr 20243.73%6.95
30 Apr 20243.82%1.77results (8-K)
15 May 20244.31%5.4610-Q filed, results (8-K)
31 May 20243.79%5.02
14 Jun 20243.53%6.38
28 Jun 20243.92%1.39
15 Jul 20242.77%2.90
31 Jul 20242.36%3.39
15 Aug 20242.41%3.4110-Q filed, results (8-K)
30 Aug 20242.30%5.74
13 Sep 20242.44%4.96
30 Sep 20242.45%5.71
15 Oct 20242.29%5.00
31 Oct 20242.23%3.5610-Q filed, results (8-K)
15 Nov 20241.72%2.55
29 Nov 20241.64%4.00
13 Dec 20241.78%4.90
31 Dec 20241.87%3.71

See also: Intra-Cellular Therapies Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.